Getinge will gradually phase out its surgical perfusion business, to focus on more profitable growth areas such as ECLS and ...

CEO Mattias Perjos said surgical perfusion has “been a struggling category” since an FDA consent decree forced Getinge off the U.S. market in 2015.

LivaNova (LIVN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Matson from ...

Stifel analysts maintained a Buy rating and a $72.00 price target for LivaNova (NASDAQ:LIVN), following news from Swedish ...

Getinge AB (GNGBF) reports robust sales growth and strategic restructuring amid market challenges and quality-related costs.

Intuitive Surgical will face competition this year from Medtronic and smaller companies like CMR Surgical and Moon Surgical ...

Getinge had record sales and we finished off the year with a strong quarter. Both order intake and net sales increased significantly, also organically, with positive performance in all regions", says ...

With a substantial 34% earnings before interest, taxes, and amortization beat in the fourth quarter, Getinge reported a ...